Skip to Content
Home > Services > Cancer > Clinical Research Trials > Clinical Trial Search > Detail
Back to Results
The purpose of this study is to learn about the safety and potential benefit of metronomic 5-fluorouracil in combination with nab®1-paclitaxel, bevacizumab, leucovorin, and oxaliplatin in treating patients with metastatic pancreatic adenocarcinoma.
A subject will be eligible for inclusion in this study only if all of the following criteria are met:
Subject has the following blood counts / Hemoglobin (Hgb) at screening:
Subject has the following blood chemistry levels at screening:
Females of childbearing potential (FOCBP) [defined as a sexually mature woman who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any time during the preceding 24 consecutive months)] must:
A subject will not be eligible for inclusion in this study if any of the following criteria apply:
Subject with high cardiovascular risk, including, but not limited to:
Kenneth A. Kuenzli II, RN864firstname.lastname@example.org
Thank you for your feedback!
Get the latest news on the health topics that matter most to you.
© 2019 Spartanburg Regional Healthcare System. All Rights Reserved.